Physician profile
Katrin Moskowitz
NPI 1285063446
$1,394.83
in general payments reported to CMS, 2019-2025
12 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $413 · 2022: $110 · 2023: $514 · 2024: $252 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.27 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.63 | 2021-2024 | |
| Gilead Sciences, INC. | $207.01 | 2021-2025 | Epclusa |
| Alkermes, INC. | $186.34 | 2021-2025 | Vivitrol, Vivitrol |
| Neurocrine Biosciences, INC. | $178.69 | 2021-2022 | |
| Uswm, LLC | $124.44 | 2023 | Lucemyra, Zimhi |
| Teva Pharmaceuticals USA, INC. | $55.10 | 2022-2023 | Austedo Xr |
| Braeburn INC. | $41.84 | 2023-2024 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $40.14 | 2023 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $33.31 | 2023-2024 | Qelbree, Qelbree |
| Indivior INC. | $32.66 | 2021-2023 | Sublocade |
| Hikma Pharmaceuticals USA | $20.24 | 2022 | |
| Pear Therapeutics (US), INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrin Moskowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.